Syncria (GlaxoSmithKline) shows mixed results in Phase III studies of Type 2 Diabetes patients

New results are reported for HARMONY 6, a 52-week randomised study comparing Syncria (albiglutide), from GlaxoSmithKline, to Lispro among patients with Type 2 Diabetes who were inadequately controlled on intermediate or long-acting insulin. In addition to previously reported results, the effect on HbA1c was maintained on continued treatment at 52 weeks (reduction from baseline of 1.01% vs 0.85%). In addition, the proportion of patients achieving a clinically meaningful HbA1c target level (ADA goal of <7.0%) by week 52 was 45 in the albiglutide arm compared to 30 p="NS" for treatment difference in the lispro arm. results of harmony 7 a 32-week head-to-head study comparing syncria 50mg to once-daily liraglutide 1.8mg demonstrated a statistically significant reduction in hba1c from baseline but did not meet the pre-specified primary endpoint of non-inferiority to liraglutide. however the proportion of patients achieving a clinically meaningful hba1c target level of more than 7.0 at week 32 was higher in the liraglutide arm 52 compared to the albiglutide arm 42. results were presented at the american diabetes association meeting.>